Healthcare > Pharmaceuticals & Biotechnology
•2430 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2430)
| Company | Market Cap | Price |
|---|---|---|
|
ABUS
Arbutus Biopharma Corporation
Imdusiran is an RNA interference therapeutic (RNAi) targeting HBV, representing the core product category.
|
$907.77M |
$4.71
+0.75%
|
|
CGEM
Cullinan Therapeutics, Inc.
Cullinan develops bispecific antibodies (CD19xCD3 and BCMAxCD3) as core assets.
|
$889.69M |
$15.03
+1.97%
|
|
TBPH
Theravance Biopharma, Inc.
Ampreloxetine is an oral small-molecule therapeutic in Phase 3 (CYPRESS) for symptomatic nOH in MSA, representing a core TBPH pipeline asset.
|
$873.09M |
$17.23
+2.68%
|
|
MRVI
Maravai LifeSciences Holdings, Inc.
Maravai produces highly modified nucleic acids (mRNA, oligonucleotides) and related inputs, including acquisitions expanding DNA/RNA production capabilities.
|
$866.85M |
$3.39
-0.59%
|
|
ANRO
Alto Neuroscience, Inc.
Company focuses on Neuropsychiatric drug development across MDD, bipolar depression, TRD, and schizophrenia using precision psychiatry.
|
$861.16M |
$27.64
+6.04%
|
|
KURA
Kura Oncology, Inc.
Kura's core business is oncology-focused biotechnology developing ziftomenib and related menin inhibitors for AML, placing it in Biotech - Oncology.
|
$842.33M |
$9.69
+8.33%
|
|
CTMX
CytomX Therapeutics, Inc.
CX-2051 is a lead antibody-drug conjugate (ADC) using the PROBODY platform, making Antibody-Drug Conjugates the direct product category.
|
$816.68M |
$4.80
-1.74%
|
|
IVA
Inventiva S.A.
Inventiva's lanifibranor is an orally administered small-molecule therapeutic for MASH, fitting the 'Oral Small Molecule Therapeutics' tag.
|
$788.99M |
$5.68
+0.98%
|
|
GYRE
Gyre Therapeutics, Inc.
Gyre Therapeutics develops and commercializes small-molecule therapeutics (lead Hydronidone/F351 and multiple pipeline agents, plus licensed products) for fibrotic diseases, which fits the 'Oral Small Molecule Therapeutics' category.
|
$780.30M |
$8.12
+2.78%
|
|
STKL
SunOpta Inc.
The company functions as a co-manufacturer and private label partner, providing manufacturing services to brands and retailers.
|
$764.86M |
$6.48
-0.31%
|
|
DSGN
Design Therapeutics, Inc.
Company develops small-molecule therapeutics (GeneTAC) targeting inherited nucleotide repeat disorders.
|
$747.36M |
$13.12
+4.88%
|
|
SLS
SELLAS Life Sciences Group, Inc.
GPS is an oncology-focused therapeutic developed by SELLAS, targeting cancer antigens (WT1) and used as an immunotherapy.
|
$743.55M |
$5.24
+6.19%
|
|
CSTL
Castle Biosciences, Inc.
Castle Biosciences provides oncology biomarker diagnostics (DecisionDx-Melanoma, DecisionDx-SCC, TissueCypher BE) using gene expression profiling and spatial omics, aligning with Biotech - Oncology.
|
$731.18M |
$25.05
+2.00%
|
|
DBVT
DBV Technologies S.A.
Viaskin Peanut EPIT patch is a drug-delivery platform; DBV Technologies directly develops and commercializes this patch-based immunotherapy.
|
$721.78M |
$21.34
+3.54%
|
|
IRWD
Ironwood Pharmaceuticals, Inc.
LINZESS is a peptide-based therapeutic, aligning with the Peptide Therapeutics investable theme.
|
$720.67M |
$4.42
+2.19%
|
|
ATXS
Astria Therapeutics, Inc.
Astria Therapeutics develops monoclonal antibody therapeutics (navenibart and STAR-0310).
|
$709.95M |
$12.56
-0.16%
|
|
ARVN
Arvinas, Inc.
Lead program ARV-471 (vepdegestrant) is an oncology-focused asset, reflecting Arvinas' core business in cancer therapeutics and PROTAC technology.
|
$706.47M |
$10.97
-0.23%
|
|
HYEX
Healthy Extracts Inc.
Exclusive rights to an oral delivery technology for nutritional supplements, a distinctive platform that differentiates the company’s product delivery.
|
$703.31M |
$2.30
|
|
PRME
Prime Medicine, Inc.
Directly develops gene editing therapeutics (Prime Editing) and the core therapeutic platform, i.e., gene therapy.
|
$687.75M |
$3.81
+3.81%
|
|
DRUG
Bright Minds Biosciences Inc.
Directly relates to development of neuropsychiatric/CNS therapeutics targeting serotonin receptors.
|
$686.46M |
$89.61
+1.08%
|
|
LXRX
Lexicon Pharmaceuticals, Inc.
Lexicon's pipeline includes oral small-molecule therapeutics pilavapadin (LX9211) and LX9851; these are oral small-molecule drugs, a major product category in their portfolio.
|
$679.56M |
$1.89
+2.72%
|
|
SLDB
Solid Biosciences Inc.
Solid Biosciences is developing viral-vector gene therapies (SGT-3.00, SGT-212, SGT-501) and related products, fitting squarely under Biotech - Gene Therapy.
|
$672.37M |
$8.61
+2.62%
|
|
ETON
Eton Pharmaceuticals, Inc.
KHINDIVI (ET-400), ET-600, ET-700, and ET-800 involve oral/ready formulations (e.g., desmopressin, hydrocortisone, zinc) consistent with the Oral Small Molecule Therapeutics category.
|
$671.51M |
$25.05
+2.52%
|
|
BIOA
BioAge Labs, Inc.
BioAge's lead program BGE-102 is an oral small-molecule therapeutic, and APJ agonists are being developed for obesity, fitting the 'Oral Small Molecule Therapeutics' investable theme.
|
$662.96M |
$18.48
+8.77%
|
|
PROK
ProKidney Corp.
Core product is rilparencel (REACT), an autologous cell therapy for preserving kidney function in CKD, fitting the Biotech - Cell Therapy category.
|
$656.25M |
$2.23
-0.22%
|
|
KE
Kimball Electronics, Inc.
Strategic expansion into Contract Manufacturing Organizations for medical devices aligns with KE's Medical CMO focus.
|
$652.51M |
$26.83
+1.48%
|
|
CMPS
COMPASS Pathways plc
Represents the company's focus on developing neuropsychiatric drugs in the CNS space.
|
$639.47M |
$6.66
-0.08%
|
|
OCGN
Ocugen, Inc.
Ocugen's modifier gene therapy platform and lead retinal candidates (OCU400/OCU410) are gene therapy products targeting vision disorders.
|
$621.52M |
$2.00
+3.37%
|
|
SRDX
Surmodics, Inc.
The company provides proprietary drug-delivery platform technologies used on medical devices (SurVeil DCB) and related platforms.
|
$614.58M |
$42.98
|
|
MGTX
MeiraGTx Holdings plc
Core business involves developing gene therapies using AAV vectors and a riboswitch platform; MeiraGTx is a clinical-stage biotechnology company focused on genetic medicines.
|
$607.38M |
$7.40
-1.99%
|
|
FDMT
4D Molecular Therapeutics, Inc.
FDMT is a gene therapy-focused biotech company developing therapeutic candidates using its proprietary vector platform (lead programs 4D-150 and 4D-710).
|
$599.35M |
$10.50
+4.37%
|
|
PSNL
Personalis, Inc.
Biomarker-driven companion diagnostics align with PSNL's tumor-informed MRD testing framework.
|
$597.65M |
$6.72
+0.90%
|
|
ASPI
ASP Isotopes Inc. Common Stock
ASPI’s PET Labs Radiopharmaceuticals production and enriched isotopes are delivered as a core product line.
|
$595.21M |
$5.38
+5.28%
|
|
RIGL
Rigel Pharmaceuticals, Inc.
Rigel's core products are oncology/hematology therapies (TAVALISSE, REZLIDHIA, GAVRETO), fitting Biotech - Oncology.
|
$588.65M |
$32.39
+1.95%
|
|
PRTA
Prothena Corporation plc
Prothena's core assets are monoclonal antibody therapeutics (PRX012, PRX019, PRX123, etc.) across neurodegenerative diseases, including Alzheimer's and other indications.
|
$586.75M |
$10.88
+3.37%
|
Showing page 10 of 25 (2430 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
